HPE Managing CINV pocket guide 2019 | Page 89

70–80 % of patients who do not receive CINV prophylaxis experience nausea and/or vomiting after chemotherapy 2 Medical complications Affects quality of life Significant morbidity, poor nutrition, muscle wasting, dehydration, anxiety, physical damage to the stomach, discontinuation of anticancer therapy, compromised survival outcomes 4–8 Up to 90% of patients reporting decreased daily functioning when CINV prevention is inadequate 5